# OnCo record pdl1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/pdl1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "pdl1" ;
  schema:name "PD-L1"@en ;
  schema:description "PD-L1 is the tumour's side of the PD-1 brake, and also the biomarker that decides who gets immunotherapy."@en ;
  schema:url <https://onco.cc/targets/pdl1/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PD-L1>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120217>, <https://www.uniprot.org/uniprotkb/Q9NZQ7/entry>, <https://www.ncbi.nlm.nih.gov/gene/29126> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21100639> ;
  schema:citation <https://en.wikipedia.org/wiki/PD-L1>, <https://doi.org/10.1073/pnas.91.23.10962>, <https://doi.org/10.1038/nrc2542>, <https://doi.org/10.1056/NEJMoa0905680> ;
  onco:tag "checkpoint", "biomarker" ;
  schema:alternateName "CD274" ;
  onco:targetClass "checkpoint" ;
  onco:firstDescribed "1999"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/pd-l1-tc-score/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/pd-l1-cps/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/io102-io103/>, <https://onco.cc/drugs/acasunlimab/>, <https://onco.cc/drugs/sasanlimab/>, <https://onco.cc/drugs/pf-08046054/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/ssgj-706/>, <https://onco.cc/drugs/hb0036/> ;
  onco:companies <https://onco.cc/companies/compass-therapeutics/>, <https://onco.cc/companies/insight-molecular-diagnostics/>, <https://onco.cc/companies/io-biotech/>, <https://onco.cc/companies/onc-ai/>, <https://onco.cc/companies/oncohost/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/myeloid-suppression-axis/> ;
  onco:terms <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/nct06107374/>, <https://onco.cc/trials/nct07169552/>, <https://onco.cc/trials/nct06631079/>, <https://onco.cc/trials/nct07444437/>, <https://onco.cc/trials/nct07293754/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/>, <https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/>, <https://onco.cc/key-papers/paper-impassion130-n-engl-j-med-2018/>, <https://onco.cc/key-papers/paper-keynote-355-nejm-2022/>, <https://onco.cc/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/>, <https://onco.cc/key-papers/paper-albrecht-pdl1-western-gallbladder-cancers-2021/>, <https://onco.cc/key-papers/paper-patil-gallbladder-immune-microenvironment-aimm-2021/> .